Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will ...

South Korean drug maker Samsung BioLogics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of ...

Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

According to a regulatory filing, the company will establish a new entity, Samsung Epis Holdings, which will later ...

South Korean drug maker Samsung BioLogics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

while leading bio company Samsung Biologics climbed 2.63 percent. Battery manufacturers and shipbuilders also enjoyed positive trading. Leading battery manufacturer LG Energy Solution rose 1.25 ...

Samsung Biologics Co. Ltd. plans to establish a new holding company and to spin off its biosimilar division, Samsung Bioepis Co. Ltd., by October. The corporate restructuring will draw clear lines ...

With the Samsung Galaxy S25 series now here we’re looking ahead to Samsung’s next big smartphone launch, which in all likelihood will consist of the brand's 2025 foldables. The Samsung Galaxy ...